Journal ArticleDOI
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and Nephropathy
David Aguilar,Samuel Z. Goldhaber,Daniel J. Gans,Andrew S. Levey,Jerome G. Porush,Julia B. Lewis,Jean-Lucien Rouleau,Tomas Berl,Edmund J. Lewis,Marc A. Pfeffer +9 more
Reads0
Chats0
TLDR
During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction, accounting for 14% of all first nonfatal MIs.Abstract:
During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.read more
Citations
More filters
Journal ArticleDOI
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
David C Burgess,David M. Hunt,Liping Li,Diana Zannino,Elizabeth A. Williamson,Timothy M. E. Davis,Markku Laakso,Y. Antero Kesäniemi,Jun Zhang,Raymond W. Sy,Seppo Lehto,Stewart Mann,Anthony C Keech +12 more
TL;DR: Fenofibrate reduces therisk of a first MI and substantially reduces the risk of further clinical CVD events after silent MI, supporting its use in type 2 diabetes.
Journal ArticleDOI
Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study
Zhu Ming Zhang,Pentti M. Rautaharju,Ronald J. Prineas,Carlos J. Rodriguez,Laura Loehr,Wayne D. Rosamond,Dalane W. Kitzman,David Couper,Elsayed Z. Soliman +8 more
TL;DR: Race and sex differences in the incidence and prognostic significance of SMI exist that may warrant considering SMI in personalized assessments of coronary heart disease risk and are associated with poor prognosis.
Journal ArticleDOI
Prevalence, consequences, and implications for clinical trials of unrecognized myocardial infarction.
TL;DR: The potential role of including unrecognized MI as a major adverse outcome in randomized clinical trials of agents aimed at reducing cardiovascular morbidity is explored.
Journal ArticleDOI
Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations
Benjamin J Epstein,John G. Gums +1 more
TL;DR: ACE inhibitors and ARBs should not be considered interchangeable, even among patients with a documented history of ACE inhibitor intolerance, and can be considered a second-line alternative in such patients with the realization that they have not been shown to prevent MI or prolong survival.
Journal ArticleDOI
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes (RECORD) study
Michael R. MacDonald,Mark C. Petrie,Philip Home,Michel Komajda,Nigel P. Jones,Henning Beck-Nielsen,Ramon Gomis,Markolf Hanefeld,Stuart J. Pocock,Paula S. Curtis,John J.V. McMurray +10 more
TL;DR: Although the prevalence and incidence of myocardial infarction was low, unrecognized Q-wave myocardia infarctions made up a substantial proportion of all events.
References
More filters
Journal ArticleDOI
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
Edmond J Lewis,Lawrence G. Hunsicker,William R. Clarke,Tomas Berl,Marc A. Pohl,Julia B. Lewis,Eberhard Ritz,Robert C. Atkins,Richard D. Rohde,Itamar Raz +9 more
TL;DR: The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
Journal ArticleDOI
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
Hertzel C. Gerstein,Johannes F.E. Mann,Qilong Yi,Bernard Zinman,Sean F. Dinneen,Byron J. Hoogwerf,Jean Pierre Hallé,James B. Young,Andrew Rashkow,Carol Joyce,Shah Nawaz,Salim Yusuf +11 more
TL;DR: The results indicate that any degree of albuminuria is a risk factor for CV events in individuals with or without DM; the risk increases with the ACR, starting well below the microalbuminuria cutoff.
Journal ArticleDOI
Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study.
TL;DR: It is concluded that unrecognized infarction are common and have as serious a prognosis as recognized infarctions.
Journal ArticleDOI
Coronary heart disease in the Western Collaborative Group Study. A follow-up experience of 4 and one-half years.
TL;DR: A significantly increased incidence of coronary heart disease was found to be associated with parental history of CHD, elevated systolic or diastolic blood pressure, cigarette smoking, higher serum levels of cholesterol, triglyceride and beta lipoproteins, and the Type A behavior pattern.
Journal ArticleDOI
Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy
Tomas Berl,Lawrence G. Hunsicker,Julia B. Lewis,Marc A. Pfeffer,Jerome G. Porush,Jean L. Rouleau,Paul L. Drury,Enric Esmatjes,Donald E. Hricik,Chirag R. Parikh,Itamar Raz,Philippe Vanhille,Thomas B. Wiegmann,Bernard M. Wolfe,Francesco Locatelli,Samuel Z. Goldhaber,Edmund J. Lewis +16 more
TL;DR: The analysis of the cardiovascular end points that were monitored as secondary end points in the Irbesartan Diabetic Nephropathy Trial (IDNT) was reported to assess whether an angiotensin II receptor blocker or a calcium-channel blocker alters the risk for cardiovascular events beyond those observed by blood pressure reduction alone without such agents.